Perspective Therapeutics Inc [CATX] stock is trading at $2.05, up 5.13%. An important factor to consider is whether the stock is rising or falling in short-term value. The CATX shares have gain 13.89% over the last week, with a monthly amount drifted -20.85%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Perspective Therapeutics Inc [AMEX: CATX] stock has seen the most recent analyst activity on March 13, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $10. Previously, Scotiabank started tracking the stock with Sector Outperform rating on March 07, 2025, and set its price target to $15. On November 25, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $5 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $20 on October 24, 2024. Wedbush initiated its recommendation with a Outperform and recommended $25 as its price target on October 01, 2024. Truist started tracking with a Buy rating for this stock on September 25, 2024, and assigned it a price target of $21. In a note dated July 25, 2024, BofA Securities initiated an Buy rating and provided a target price of $24 on this stock.
Perspective Therapeutics Inc [CATX] stock has fluctuated between $1.60 and $19.05 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Perspective Therapeutics Inc [AMEX: CATX] shares were valued at $2.05 at the most recent close of the market. An investor can expect a potential return of 875.61% based on the average CATX price forecast.
Analyzing the CATX fundamentals
Perspective Therapeutics Inc [AMEX:CATX] reported sales of 1.45M for the trailing twelve months, which represents a drop of -89.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.27 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.9500 points at the first support level, and at 1.8500 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.1200, and for the 2nd resistance point, it is at 2.2000.
Ratios To Look Out For
For context, Perspective Therapeutics Inc’s Current Ratio is 12.68. On the other hand, the Quick Ratio is 12.68, and the Cash Ratio is 3.38. Considering the valuation of this stock, the price to sales ratio is 104.69, the price to book ratio is 0.50.
Transactions by insiders
Recent insider trading involved Spoor Johan M., Chief Executive Officer, that happened on Mar 28 ’25 when 22026.0 shares were purchased. Chief Executive Officer, Spoor Johan M. completed a deal on Mar 28 ’25 to buy 4650.0 shares. Meanwhile, Director Williamson Robert F III bought 38145.0 shares on Mar 31 ’25.
